Introduction
The Etopor 100 mg (Etoposide) Injection is a podophyllotoxin-derived chemotherapy agent designed for the first-line treatment of small cell lung cancer (SCLC) in combination with other chemotherapeutic drugs. Manufactured by Eskayef Pharmaceuticals Ltd., a leader in oncology innovation, and supplied globally by Onco Solution, this injection disrupts cancer cell proliferation by inhibiting topoisomerase II, a critical enzyme for DNA replication. Trusted for its targeted efficacy and well-characterized pharmacokinetics, the Etopor 100 mg (Etoposide) Injection is a cornerstone in managing aggressive malignancies, offering hope to patients with limited treatment options.
Key Benefits
- Topoisomerase II Inhibition: Prevents DNA repair and replication, inducing apoptosis in cancer cells.
- Predictable Pharmacokinetics: Biphasic elimination ensures consistent dosing with minimal accumulation.
- Combination Therapy Synergy: Enhances outcomes when paired with other chemotherapeutic agents.
- Global Accessibility: Supplied by Onco Solution, ensuring reliable access to life-saving therapies.
Indications
The Etopor 100 mg (Etoposide) Injection is indicated for:
- Small Cell Lung Cancer (SCLC): First-line treatment in combination with other approved chemotherapeutic agents.
Pharmacology
Mechanism of Action
Etpor contains etoposide, a semisynthetic podophyllotoxin derivative that inhibits topoisomerase II, an enzyme essential for DNA unwinding during replication. By stabilizing the DNA-topoisomerase II complex, etoposide causes double-strand DNA breaks, halting cell cycle progression at the G2 phase and triggering apoptosis.
Pharmacokinetics
- Distribution: Biphasic process with a distribution half-life of 1.5 hours.
- Elimination: Terminal half-life of 4–11 hours; total body clearance ranges from 33–48 mL/min.
- Linearity: AUC and Cmax increase linearly with doses of 100–600 mg/m².
Dosage & Administration
Small Cell Lung Cancer (SCLC)
- Standard Dose: 35–50 mg/m²/day for 4–5 days per cycle, combined with other chemotherapies.
- Administration:
- Administer via slow intravenous infusion over 30–60 minutes to prevent hypotension.
- Avoid rapid IV push or undiluted solutions.
Renal Impairment Adjustments
| Creatinine Clearance | Dose Adjustment |
|---|---|
| >50 mL/min | 100% of dose |
| 15–50 mL/min | 75% of dose |
| <15 mL/min | Further reduction* |
Consult physician for individualized dosing.
Drug Interactions
- Cyclosporine: High doses (>2000 ng/mL) increase etoposide exposure by 80%.
- Laboratory Monitoring: Perform CBCs before each cycle and during therapy to track myelosuppression.
Contraindications
- Hypersensitivity to etoposide or any component of the formulation.
Side Effects
Common Reactions
- Hematologic: Severe myelosuppression (neutrophil nadir: 7–14 days; platelet nadir: 9–16 days).
- Gastrointestinal: Nausea, vomiting (manage with antiemetics), mucositis.
- Allergic: Rash, pruritus, flushing.
Serious Risks
- Anaphylaxis: Chills, fever, bronchospasm, hypotension (incidence: 0.7–2% with IV use).
- Secondary Leukemia: Rare reports of AML post-treatment.
- Pulmonary Toxicity: Interstitial pneumonitis/fibrosis.
Pregnancy & Lactation
- Pregnancy Category D: Contraindicated due to fetal harm risk.
- Lactation: Avoid breastfeeding; etoposide is excreted in human milk.
Precautions & Warnings
- Myelosuppression:
- Monitor CBCs weekly; withhold therapy if neutrophils <500/mm³ or platelets <50,000/mm³.
- Hypersensitivity Management:
- Premedicate with antihistamines; terminate infusion immediately for reactions.
- Hepatic/Renal Monitoring:
- Adjust doses for renal impairment; monitor liver function in patients with low serum albumin.
Therapeutic Class
- Cytotoxic Chemotherapy: Podophyllotoxin derivatives.
Storage & Handling
- Unopened Vials: Refrigerate at 2°C–8°C; protect from light.
- Stability: 24 months under refrigeration.
- Disposal: Follow institutional protocols for cytotoxic waste.
Why Choose Etopor 100 mg (Etoposide) Injection?
Proven Efficacy: Clinically validated for SCLC with synergistic combination regimens.
- Quality Assurance: Produced by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified manufacturer with 30+ years of excellence.
- Global Distribution: Supplied by Onco Solution, bridging healthcare gaps in Asia, Africa, and Europe.
Conclusion
The Etopor 100 mg (Etoposide) Injection is a vital tool in combating small cell lung cancer, offering precision-driven cytotoxicity with manageable tolerability. By integrating this therapy into treatment protocols, clinicians align with Eskayef Pharmaceuticals Ltd.’s commitment to quality and Onco Solution’s mission to democratize access to advanced oncology care.
